BioPharmSignal logoBioPharmSignal

Biotech News

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANI Pharmaceuticals (ANIP)ANI PharmaceuticalsCompany update

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).

Related news

ANIPANI Pharmaceuticals2026-11-05 06:33 EST

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-04-20 10:50 EST

ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity

AMRXAmneal Pharmaceuticals2026-06-05 12:00 EST

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

CHRSCoherus BioSciences, Inc.2026-01-05 14:30 EST

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

AMRXAmneal Pharmaceuticals2026-09-18 20:01 EST

Amneal Announces FDA Approval and Launch of Lanreotide Injection

View all latest news

ANI Pharmaceuticals

Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone...

Recent company news

ANIPANI Pharmaceuticals2026-11-05 11:51 EST

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

ANIPANI Pharmaceuticals2026-11-05 11:50 EST

REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-11-05 06:33 EST

ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business

ANIPANI Pharmaceuticals2026-11-03 11:55 EST

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

ANIPANI Pharmaceuticals2026-10-23 10:55 EST

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

Stock data

Close
69.62 USD
Market cap
1.7B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States